Management of osteoporosis in the aging male: Focus on zoledronic acid

(1076) Article views

Authors: Paul K Piper Jr, Ugis Gruntmanis

Published Date June 2009 , Volume 2009:4

Paul K Piper Jr¹, Ugis Gruntmanis^1,2

¹Division of Endocrinology and Metabolism, University of Texas Southwestern Medical Center, Dallas, TX USA; ²North Texas Veterans Affairs Medical Center, Dallas, TX USA

Abstract: Osteoporosis in the aging male remains an important yet under-recognized and undertreated disease. Current US estimates indicate that over 14 million men have osteoporosis or low bone mass, and men suffer approximately 500,000 osteoporotic fractures each year. Men experience fewer osteoporotic fractures than women but have higher mortality after fracture. Bisphosphonates are potent antiresorptive agents that inhibit osteoclast activity, suppress in vivo markers of bone turnover, increase bone mineral density, decrease fractures, and improve survival in men with osteoporosis. Intravenous zoledronic acid may be a preferable alternative to oral bisphosphonate therapy in patients with cognitive dysfunction, the inability to sit upright, or significant gastrointestinal pathology. Zoledronic acid (Reclast) is approved in the US as an annual 5 mg intravenous infusion to treat osteoporosis in men. The zoledronic acid (Zometa) 4 mg intravenous dose has been studied in the prevention of bone loss associated with androgen deprivation therapy.

Keywords: male osteoporosis, bisphosphonates, zoledronic acid